Pathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells
Rüdiger Eming(Philipps University of Marburg), Michael Hertl(Universitätsklinikum Gießen und Marburg), Tina Hennerici(Philipps University of Marburg), Claudio Feliciani(University of Parma), Kevin Visconti(University of Tennessee Medical Center), Johan Bäcklund(Karolinska Institutet), Sebastian Willenborg(University of Cologne), Jessica Wohde(Philipps University of Marburg), Grete Sønderstrup(Stanford University), Rikard Holmdahl(Uppsala University)
Cited by 73
Related Papers
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Diagnosis and management of pemphigus: Recommendations of an international panel of experts
|Journal of the American Academy of Dermatology|2018|384
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|370
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)
|Journal of the European Academy of Dermatology and Venereology|2020|332